Drug Profile
Research programme: RECK activators - Oncolys BioPharma
Alternative Names: Reversion-inducing-cysteine-rich protein with kazal motifs activators - Oncolys BioPharmaLatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Oncolys BioPharma
- Developer Kyoto University; Oncolys BioPharma
- Class Antineoplastics
- Mechanism of Action Gene stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer